HAVCR2 and neoplasm: Several clinical trials are also working on combined blockade of TIM3/galectin-9 and PD-1/PD-L1 pathways (NCT02817633, NCT03099109, NCT02608268), and other clinical trials focusing on the combination of anti-TIM3/galectin-9 and anti-PD-1/PD-L1 in tumor immunotherapy will be the new strategy.